Κλινική Τεκμηρίωση

A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomized, double-blind, placebo-controlled proof-of-concept clinical trial

Marios C Pantzaris et al

Objective: To assess whether three novel interventions, formulated based on a systems medicine therapeutic concept, reduced disease activity in patients with relapsing–remitting multiple sclerosis (MS) who were either treated or not with disease modifying treatment.

Design: A 30-month randomized, double-blind, placebo-controlled, parallel design, phase II proof-of-concept clinical study.

Settings: Cyprus Institute of Neurology and Genetics.